hiv | CARLAT PUBLISHING

Management of Depression and Neurocognitive Impairment in Patients With HIV

January 15, 2023

Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications.

Harm Reduction Strategies—A Primer

February 11, 2020

To minimize harm and optimize safety among people who use drugs, particularly injections drugs, learn the nuts and bolts of naloxone distribution, syringe exchange, pre-exposure prophylaxis (PrEP) for HIV prevention, and fentanyl testing.

EXPERT Q&A

The Clinician’s Role: Reducing Harm Among People Who Use Drugs

February 11, 2020

Kimberly Sue, MD, PhD

Kimberly Sue, MD, PhD
Medical Director of the Harm Reduction Coalition (www.harmreduction.org). Attending physician at Rikers Island Correctional Health Services, NY. Dr. Sue has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction researcher and medical director of the Harm Reduction Coalition shares her approach to patients and provides state-specific resources for clinicians interested in connecting with harm reduction resources locally.

How to Talk to Patients About the Risk of Opioid Overdose

February 11, 2020

How do you engage patients in discussion surrounding overdose risk? Learn some evidence-based strategies that will build trust, be accessible and understandable to patients, and empower them to use as safely as possible.

Screening and Prophylaxis of Infectious Diseases in Addiction Practice

November 22, 2019

Sandra Springer, MD

Sandra Springer, MD

Associate Professor of Medicine in the Department of Internal Medicine, Yale School of Medicine. Director of the Infectious Disease Clinic (Newington) and Attending Infectious Disease Physician (West Haven), VA Connecticut Healthcare System.

Dr. Springer has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we invite Dr. Sandra Springer to walk us through the various screenings for infectious diseases ranging from HIV to Hepatitis A, Hepatitis B, and Hepatitis C, as well as Tuberculosis.

PrEP: Introduction to the Basics

November 22, 2019

With the rate of new HIV infections at just under 40,000 new infections per year, it is important for addiction practitioners to be on the front lines of HIV prevention. This article and corresponding table cover the pre-exposure prophylaxis (PrEP) with Truvada.